Cited by 452BRCA gene mutations in cancerBreast Lesions and CarcinomasBreast Cancer Treatment Studies

The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Verhoog, LC, Brekelmans, CTM, Seynaeve, C, van den Bosch, LMC, Dahmen, G, van Geel, AN, Tilanus-Linthorst, MMA, Bartels, CCM, Wagner, A, van den Ouweland, A, Devilee, P, Meijers-Heijboer, EJ, Klijn, JGM·1998·The Lancet

DOI 10.1016/s0140-6736(97)07065-7

Open this paper in CoChat — free account

Abstract

Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration.Methods We estimated disease-free and overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis.Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(97)07065-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
The statistical analysis of failure time data
Herson, J. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90009-x · Cited by 1,391
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Age as prognostic factor in premenopausal breast carcinoma
de la Rochefordière, A., Campana, F., Fenton, J., Vilcoq, J. R., Fourquet, A., Asselain, B. J. R., Scholl, S. M., Pouillart, P., Durand, J., & Magdelénat, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92407-k · Cited by 481
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Self-citation
Tumour biological features of BRCA1-induced breast and ovarian cancer
Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V., & Olsson, H. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 344

Show all 31 references

Research works printed but not linked: 3

Lynch, 1993, Increased proliferation in hereditary breast cancer, Proc ASCO, 12, 82
Lynch, 1994, Distinctive clinicopathological features of BRCA1 linked hereditary breast cancer, Proc ASCO, 13, 56
Solin, 1996, Breast cancer in young women: the University of Pennsylvania experience—breast cancer: advances in biology and therapeutics, John Libbey Eurotext, 351

Sorted by citations

Items 101–200 of 450

Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Foulkes, W. D., Chappuis, P. O., Wong, N., Brunet, J.-S., Vesprini, D., Rozen, F., Yuan, Z. Q., Pollak, M. N., Kuperstein, G., Narod, S. A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008340723974 · Cited by 86
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching, P. A., Yadav, S., Hu, C., Wunderle, M., Häberle, L., Hart, S. N., Rübner, M., Polley, E. C., Lee, K. Y., Gnanaolivu, R. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01200 · Cited by 86
BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling
Nicoletto, M. O., Donach, M. E., Nicolo, A. D., Artioli, G., Banna, G. L., & Monfardini, S. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0233 · Cited by 83
Earlier detection of breast cancer by surveillance of women at familial risk.
Tilanus-Linthorst, M., Bartels, C., Obdeijn, A. I. M., & Oudkerk, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00337-8 · Cited by 91
Self-citation
Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost
Lippman, S. M., & Brown, P. H. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1809 · Cited by 81
Evolving perspectives in contralateral breast cancer.
Dawson, L., Chow, E., & Goss, P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00208-1 · Cited by 88
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Kim‐Sing, C., Olopade, O. I., Domchek, S. M., Eisen, A. F., Foulkes, W. D., Rosen, B. P., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1336-7 · Cited by 82
Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT)
Vu-Nishino, H., Tavassoli, F. A., Ahrens, W. A., & Haffty, B. G. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.01.008 · Cited by 80
Fatty acids, biliary bile acids, lipid peroxidation products and gallbladder carcinogenesis.
Yoon, H., Benamouzig, R., Little, J., François‐Collange, M., & Tomé, D. (2000) · PubMed · Cited by 80
Survival in early-onset BRCA1 breast-cancer patients
Ansquer, Y., Gautier, C., Fourquet, A., Asselain, B. J. R., & Stoppa‐Lyonnet, D. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79248-5 · Cited by 80
Grand multiparity and the risk of breast cancer: population-based study in Finland
Hinkula, M., Pukkala, ., Kyyrönen, P., & Kauppila, A. (2001) · Cancer Causes & Control · doi:10.1023/a:1011253527605 · Cited by 79
Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation
van Roosmalen, M. S., Stalmeier, P. F. M., Verhoef, L. C. G., Hoekstra‐Weebers, J. E. H. M., Oosterwijk, J. C., Hoogerbrugge, N., Moog, U., & van Daal, W. A. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601525 · Cited by 79
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.
Contant, C., Menke-Pluijmers, M., Seynaeve, C., Meijers-Heijboer, E. J., Klijn, J. G., Verhoog, L., Wai, R. T. J., Eggermont, A., & van Geel, A. V. (2002) · European Journal of Surgical Oncology · doi:10.1053/ejso.2002.1279 · Cited by 78
Self-citation
Hereditary breast cancer growth rates and its impact on screening policy
Tilanus‐Linthorst, M. M. A., Kriege, M., Boetes, C., Hop, W. C. J., Obdeijn, I.-M., Oosterwijk, J. C., Peterse, H. L., Zonderland, H. M., Meijer, S., Eggermont, A. M. M., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.034 · Cited by 77
Self-citation
The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland
Stacey, S., Sulem, P., Johannsson, O. T., Helgason, A., Guðmundsson, J., Kostic, J. P., Kristjánsson, K., Jonsdottir, T. E., Sigurdsson, H., Hrafnkelsson, J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030217 · Cited by 75
Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer.
Chabner, E., Nixon, A., Gelman, R., Hetelekidis, S., Recht, A., Bornstein, B., Connolly, J., Schnitt, S., Silver, B., Manola, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2045 · Cited by 78
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri, S. A. J., Krumroy, L. M., Elson, P. J., Budd, G. T., Darlington, G., Myles, J., Tubbs, R. R., & Casey, G. (2001) · PubMed · Cited by 73
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3045 · Cited by 73
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area
Pohlreich, P., Zikán, M., Stribrna, J., Kleibl, Z., Janatová, M., Kotlas, J., Židovská, J., Novotný, J., Petruželka, L., Szabo, C., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1282 · Cited by 75
Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics
Coate, L. E., Cuffe, S. D., Horgan, A. M., Hung, R. J., Christiani, D. C., & Liu, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2336 · Cited by 73
Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery
Salhab, M., Bismohun, S., & Mokbel, K. (2010) · BMC Women s Health · doi:10.1186/1472-6874-10-28 · Cited by 70
Benefits and Costs of Screening Ashkenazi Jewish Women for BRCA1 and BRCA2
Grann, V. R., Whang, W., Jacobson, J. S., Heitjan, D. F., Antman, K. H., & Neugut, A. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.494 · Cited by 70
The complex relationship between BRCA1 and ERα in hereditary breast cancer
Gorski, J. J., Kennedy, R., Hosey, A. M., & Harkin, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0640 · Cited by 61
Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006
Liebens, F., Carly, B., Pastijn, A., & Rozenberg, S. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.07.019 · Cited by 69
Ethnicity related differences in the survival of young breast carcinoma patients
Newman, L. A., Bunner, S. H., Carolin, K. A., Bouwman, D. L., Kosir, M. A., White, M., & Schwartz, A. G. (2002) · Cancer · doi:10.1002/cncr.10639 · Cited by 69
Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers
El-Tamer, M., Russo, D., Troxel, A., Bernardino, L. P., Mazziotta, R., Estabrook, A., Ditkoff, B., Schnabel, F., & Mansukhani, M. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.05.018 · Cited by 76
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Schuyer, M., & Berns, E. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00117-3 · Cited by 73
Awareness, Perceptions, and Provider Recommendation Related to Genetic Testing for Hereditary Breast Cancer Risk among At‐Risk Hispanic Women: Similarities and Variations by Sub‐Ethnicity
Vadaparampil, S. T., McIntyre, J., & Quinn, G. P. (2010) · Journal of Genetic Counseling · doi:10.1007/s10897-010-9316-y · Cited by 65
Interaction of Waist/Hip Ratio and Family History on the Risk of Hormone Receptor-defined Breast Cancer in a Prospective Study of Postmenopausal Women
Sellers, T. A. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.3.225 · Cited by 66
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland
Eerola, H., Vahteristo, P., Sarantaus, L., nen, P. K., Pyrh�nen, S., BLOMQVIST, C. P., Pukkala, E., Nevanlinna, H. A., & Sankila, R. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1341 · Cited by 64
Prophylactic Mastectomy and Reconstruction: Clinical Outcomes and Patient Satisfaction
Spear, S. L., Schwarz, K. A., Venturi, M. L., Barbosa, T., & Alattar, A. A. (2008) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e318177415e · Cited by 63
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
The WECARE Collaborative Study Group, Reding, K. W., Bernstein, J. L., Langholz, B. M., Bernstein, L., Haile, R. W., Begg, C. B., Lynch, C. F., CONCANNON, P. J., Borg, Å., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0769-3 · Cited by 62
Cross-study validation and combined analysis of gene expression microarray data
Garrett-Mayer, E. S., Parmigiani, G., Zhong, X., Cope, L., & Gabrielson, E. W. (2007) · Biostatistics · doi:10.1093/biostatistics/kxm033 · Cited by 60
The influence of familial and hereditary factors on the prognosis of breast cancer.
Chappuis, P. O., Rosenblatt, J., & Foulkes, W. (1999) · Annals of Oncology · doi:10.1023/a:1008301314812 · Cited by 74
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 62
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer
Prajzendanc, K., Domagała, P., Hybiak, J., Ryś, J., Huzarski, T., Szwiec, M., Tomiczek‐Szwiec, J., Redelbach, W., Sejda, A., Gronwald, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32655 · Cited by 61
BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers
Palma, M., Ristori, E., Ricevuto, E., Giannini, G., & Gulino, A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.05.003 · Cited by 61
Germ line mutations associated with breast cancer susceptibility
Iau, P. T. C., Macmillan, R. D., & Blamey, R. W. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00378-6 · Cited by 59
Hormonal Prevention of Hereditary Breast Cancer
Narod, S. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb02726.x · Cited by 59
Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer
Hsu, N. C.-H., Huang, Y., Yokoyama, K. K., Chu, P., Chen, F., & Hou, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056256 · Cited by 59
HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry
Quenneville, L., Phillips, K., Özçelik, H., Parkes, R. K., Knight, J. A., Goodwin, P. J., Andrulis, I. L., & O’Malley, F. P. (2002) · Cancer · doi:10.1002/cncr.10949 · Cited by 56
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol
the POSH steering group, Eccles, D., Gerty, S. M., Simmonds, P., Hammond, V. R., Ennis, S., & Altman, D. G. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-160 · Cited by 57
Unilateral and Bilateral Breast Cancer in Women Surviving Pediatric Hodgkin's Disease
Basu, S. K., Schwartz, C. L., Fisher, S. G., Hudson, M. M., Tarbell, N. J., Muhs, A. G., Marcus, K. J., Mendenhall, N. P., Mauch, P., Kun, L. E., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.04.068 · Cited by 56
Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China
Deng, M., Chen, H., Zhu, X., Luo, M., Zhang, K., Xu, C., Hu, K., Cheng, P., Zhou, J., Zheng, S. S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32184 · Cited by 57
BRCA1/2 testing: complex themes in result interpretation.
Peshkin, B., Demarco, T. A., Brogan, B. M., Lerman, C., & Isaacs, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2555 · Cited by 65
Associations between Breast Cancer Susceptibility Gene Polymorphisms and Clinicopathological Features
Han, W., Kang, D., Park, I. A., Kim, S. W., Bae, J. Y., Chung, K., & Noh, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0834-3 · Cited by 54
Familial breast cancer: an investigation into the outcome of treatment for early stage disease
Eccles, D., Simmonds, P., Goddard, J., Coultas, M., Hodgson, S., Lalloo, F., Evans, G., & Haites, N. (2001) · Familial Cancer · doi:10.1023/a:1013867917101 · Cited by 53
Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1 -Related Breast Cancers
King, T. A., Gemignani, M. L., Li, W., Giri, D. D., Panageas, K., Bogomolniy, F., Arroyo, C. D., Olvera, N., Robson, M. E., Offit, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1283 · Cited by 53
Gene expression in inherited breast cancer
Hedenfalk, I. A., Ringnér, M., Trent, J. M., & Borg, Å. (2002) · Advances in cancer research · doi:10.1016/s0065-230x(02)84001-5 · Cited by 51
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review
Bonadona, V., Dussart, S., Voirin, N., Sinilnikova, O. M., Mignotte, H., Mathevet, P., Bremond, A. G., Treilleux, I., Martin, A., Romestaing, P., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9288-7 · Cited by 51
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
Tung, N., Miron, A., Schnitt, S. J., Gautam, S., Fetten, K., Kaplan, J., Yassin, Y., Buraimoh, A., Kim, J.-Y., Szász, A. M., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2776 · Cited by 50
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
Rajkumar, T., Soumittra, N., Nancy, N. K., Swaminathan, R., Veluswami, S., & Shanta, V. (2003) · PubMed · Cited by 50
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression
Templeton, A. J., Gonzalez, L. D., Vera-Badillo, F., Tibau, A., Goldstein, R., Šeruga, B., Srikanthan, A., Pandiella, A., Amir, E., & Ocaña, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154789 · Cited by 53
Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research
Tracy, M., Rosenberg, S. M., Dominici, L. S., & Partridge, A. H. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2643-6 · Cited by 49
Systematic review of epidemiological studies on meat, dairy products and egg consumption and risk of colorectal adenomas
Yoon, H., Benamouzig, R., Little, J., François‐Collange, M., & Tomé, D. (2000) · European Journal of Cancer Prevention · doi:10.1097/00008469-200006000-00002 · Cited by 49
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48
Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients
Fackenthal, J. D., Sveen, L., Gao, Q., Kohlmeir, E. K., Adebamowo, C., Ogundiran, T. O., Adenipekun, A. A., Oyesegun, R., Campbell, O., Rotimi, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020446 · Cited by 48
Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes
Pruss, D., Morris, B., Hughes, E., Eggington, J., Esterling, L., Robinson, B. S., van Kan, A., Fernandes, P. H., Roa, B., Gutin, A., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3065-9 · Cited by 42
Cancer genetic clinics: why do women who already have cancer attend?
Julian‐Reynier, C., Eisinger, F., Chabal, F., Aurran, Y., Bignon, Y., Noguès, C., Machelard-Roumagnac, M., Maugard, C. M., Vennin, P., & Sobol, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00164-6 · Cited by 43
ATM, radiation, and the risk of second primary breast cancer
Bernstein, J. L., WECARE Study Collaborative Group, & Concannon, P. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1344363 · Cited by 41
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer
Steinmann, D., Bremer, M., Rades, D., Skawran, B., Siebrands, C., Karstens, J. H., & Dörk, T. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2016 · Cited by 46
Mutator Phenotype ofCaenorhabditis elegansDNA Damage Checkpoint Mutants
Harris, J., Lowden, M. R., Clejan, I., Tzoneva, M., Thomas, J. H., Hodgkin, J., & Ahmed, S. C. (2006) · Genetics · doi:10.1534/genetics.106.058701 · Cited by 41
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients
Rogozińska-Szczepka, J., Utracka-Hutka, B., Grzybowska, E. A., Maka, B., Nowicka, E., Smok-Ragankiewicz, A., Zientek, H., Steffen, J. A., & Wojciechowska-Łącka, A. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh352 · Cited by 41
Breast cancer prevention: present and future
Salih, A. K., & Fentiman, I. S. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0235 · Cited by 40
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling
Wasielewski, M., Nagel, J. H. A., Brekelmans, C. T. M., Klijn, J. G. M., van den Ouweland, A., Meijers-Heijboer, H. E. J., & Schutte, M. E. M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9407-5 · Cited by 40
Self-citation
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology
Stecklein, S. R., & Jensen, R. A. (2012) · Translational research · doi:10.1016/j.trsl.2012.01.022 · Cited by 39
Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists
Ademuyiwa, F. O., Salyer, P., Tao, Y., Luo, J., Hensing, W. L., Afolalu, A., Peterson, L. L., Weilbaecher, K., Housten, A. J., Baumann, A. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01426 · Cited by 40
Breast Cancer Screening in BRCA1 Mutation Carriers: Effectiveness of MR Imaging—Markov Monte Carlo Decision Analysis
Lee, J. M., Kopans, D. B., McMahon, P. M., Halpern, E. F., Ryan, P. D., Weinstein, M. C., & Gazelle, G. S. (2008) · Radiology · doi:10.1148/radiol.2463070224 · Cited by 45
Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes
Nagel, J. H. A., Peeters, J. K., Smid, M., Sieuwerts, A. M., Wasielewski, M., de Weerd, V., Trapman-Jansen, A., van den Ouweland, A., Brüggenwirth, H. T., van IJcken, W. F. J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1588-x · Cited by 39
Self-citation
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers
Litwiniuk, M. M., Rożnowski, K., Filas, V., Godlewski, D. D., Stawicka, M., Kaleta, R., & Bręborowicz, J. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-100 · Cited by 38
Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer
Robson, M. E. (2002) · Cancer Control · doi:10.1177/107327480200900602 · Cited by 38
Risk of breast and ovarian cancer in women with strong family histories.
Srivastava, A., McKinnon, W. C., & Wood, M. E. (2001) · PubMed · Cited by 38
The significance of gene mutations across eight major cancer types
Paul, P., Malakar, A. K., & Chakraborty, S. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2019.04.004 · Cited by 36
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. E. J., Collee, M. J., Menke‐Pluymers, M. B. E., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., van den Ouweland, A., van Geel, B., Brekelmans, C. T. M., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9781-7 · Cited by 36
Self-citation
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation
Jeng, Y., CAI-NG, S., Li, A., Furuta, S., Chew, H., Chen, P.-L., Lee, E.-Y.-H., & Lee, W.-H. (2007) · Oncogene · doi:10.1038/sj.onc.1210451 · Cited by 36
Chemoprevention for High-Risk Women: Tamoxifen and Beyond
Fabian, C. J., & Kimler, B. F. (2001) · The Breast Journal · doi:10.1046/j.1524-4741.2001.21570.x · Cited by 36
Reading between the Lines: Direct-to-Consumer Advertising of Genetic Testing
Hull, S. C., & Prasad, K. (2001) · The Hastings Center Report · doi:10.2307/3527555 · Cited by 36
Intraoperative ultrasound and other techniques to achieve negative margins
Henry‐Tillman, R., Johnson, A. T., Smith, L. F., & Klimberg, V. S. (2001) · Seminars in Surgical Oncology · doi:10.1002/ssu.1035 · Cited by 36
SERMs in chemoprevention of breast cancer
Gasco, M., Argusti, A., Bonanni, B., & DeCensi, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.017 · Cited by 36
Low-risk susceptibility alleles in 40 human breast cancer cell lines
Riaz, M. A., Elstrodt, F., Hollestelle, A., Dehghan, A., Klijn, J. G. M., & Schutte, M. E. M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-236 · Cited by 36
Self-citation
Hereditary Cancer Syndromes
Frank, T. S. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0085-hcs · Cited by 35
Cancer genetics in oncology practice
Olopade, O. I., & Pichert, G. (2001) · Annals of Oncology · doi:10.1023/a:1011176107455 · Cited by 34
Family history of breast cancer and local recurrence after breast-conserving therapy
Brekelmans, C. T. M., Voogd, A. C., Botke, G., van Geel, B. N., Rodrigus, P. T. R., Rutgers, E. J. T., Klijn, J. G. M., & Coebergh, J. W. W. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00008-8 · Cited by 34
Self-citation
BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer
Turchetti, D., Cortesi, L., Federico, M., Bertoni, C., Mangone, L., Ferrari, S., & Silingardi, V. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00287-2 · Cited by 33
Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies
Francken, A. B., Schouten, P. C., Bleiker, E. M. A., Linn, S. C., & Rutgers, E. J. T. (2013) · The Breast · doi:10.1016/j.breast.2013.07.045 · Cited by 34
Pineal Parenchymal Tumours: II
Plowman, P. N., Pizer, B. L., & Kingston, J. E. (2004) · Clinical Oncology · doi:10.1016/j.clon.2003.12.005 · Cited by 33
Clear Cell Carcinoma of the Fimbria of the Fallopian Tube in a BRCA1 Carrier Undergoing Prophylactic Surgery
Hartley, A. G. J., Rollason, T. P., & Spooner, D. A. (2000) · Clinical Oncology · doi:10.1007/s001740050011 · Cited by 33
Is Mammographic Breast Density a Breast Cancer Risk Factor in Women With BRCA Mutations?
Passaperuma, K., Warner, E., Hill, K. A., Gunasekara, A., & Yaffe, M. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5933 · Cited by 32
Contralateral prophylactic mastectomy for patients with unilateral breast cancer
Tuttle, T. M., Habermann, E. B., Abraham, A. A., Emory, T., & Virnig, B. A. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.8.1117 · Cited by 32
Contralateral breast cancer risk.
Unnithan, J., & Macklis, R. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00369-3 · Cited by 32
Tumor suppressor genes and breast cancer
Buchholz, T. A., Weil, M. M., Story, M. D., Strom, E. A., Brock, W. A., & McNeese, M. D. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:2 · Cited by 32
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
Duffy, S. W., & Nixon, R. M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600064 · Cited by 32
Inherited genetic predisposition in breast cancer
Rebbeck, T. R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11+ · Cited by 73
Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer
Møller, P., Reis, M., Evans, G., Vasen, H., Haites, N., Anderson, E., Steel, C., Apold, J., Lalloo, F., Mæhle, L., et al. (2002) · Disease Markers · doi:10.1155/1999/805420 · Cited by 34
BRCA1and Medullary Breast Cancer
Eisinger, F. (1998) · JAMA · doi:10.1001/jama.280.14.1227 · Cited by 32
Evaluation of Bias in Familial Risk Estimates: A Study of Common Cancers Using Swedish Population-based Registers
Leu, M., Reilly, M., & Czene, K. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn290 · Cited by 31
The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer
Spears, M., & Bartlett, J. (2009) · Expert opinion on therapeutic targets · doi:10.1517/14728220902911509 · Cited by 35
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Shen, D., Wu, Y., Subbarao, M., Bhat, H., Chillar, R. K., & Vadgama, J. V. (2000) · PubMed Central · Cited by 31
Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
Eeles, R. (2000) · Breast Cancer Research · doi:10.1186/bcr70 · Cited by 32
Medullary carcinoma of the breast and BRCA1 mutation
Shousha, S. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.00880.x · Cited by 33

Authors: Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., Devilee, P., Meijers-Heijboer, E., & Klijn, J.
Affiliations: Academisch Ziekenhuis Rotterdam (NL)
Erasmus University Rotterdam (NL)
Leiden University (NL)
Corresponding author: Klijn, JGM
ORCID: Wagner, A
Devilee, P
Venue: The Lancet
Publisher: Elsevier BV
Published: 1998-01
Volume: 351
Issue: 9099
Pages: 316-321
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(97)07065-7
OpenAlex: W2137086763
Cited by: 452
References: 31
Citations by year: 2026: 3 · 2025: 8 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 13 · 2014: 10 · 2013: 7 · 2012: 5
FWCI: 28.46
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: KWF Kankerbestrijding
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: hereditary breast cancer, BRCA1 mutation, sporadic breast cancer, disease-free survival, overall survival, contralateral breast cancer, estrogen receptor status, tumor characteristics, tumor recurrence, breast cancer screening
MeSH terms: Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Risk, Odds Ratio, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks